Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
− Takeda’s Dengue Vaccine Candidate (TAK-003) Prevented 83.6% of Hospitalizations and 62.0% of Dengue Illness Overall, ...
Read more− Takeda’s Dengue Vaccine Candidate (TAK-003) Prevented 83.6% of Hospitalizations and 62.0% of Dengue Illness Overall, ...
Read moreTakeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has granted priority ...
Read moreTakeda Pharmaceutical Company Limited today announced the completion of its previously-announced sale of a portfolio of ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.